close

Fundraisings and IPOs

1 60 61 62 63
Number of results: 1242
Date Company Amount Funding type Investors Therapeutic area Type of Information
2011-02-03 AB Science (France) €1.7 million credit line BNP Paribas (France) ABN AMRO (The Netherlands) Cancer - Oncology Fundraising
2011-02-03 Digna Biotech (Spain), Centro de Investigación Médica Aplicada (CIMA) de la Universidad de Navarra (Spain) € 1.3 million grant European Union Rare diseases Grant
2011-02-03 to-BBB (The Netherlands) €4 million  Series B investment round Jonghoud International BV (The Netherlands) - Industrial Bank of Taiwan Management Corporation (IBTM) (Taiwan) - Aescap Venture  (The Netherlands) - Antea Participaties (The Netherlands) Cancer - Oncology Fundraising
2011-02-02 Scil Proteins (Germany) €24 million financing round BioNet Holding Cancer - Oncology Fundraising
2011-02-01 Mologen (Germany) €10 million private placement Cancer - Oncology - Infectious diseases Private placement
2011-02-01 ActoGeniX (Belgium) €0.53 million grant Flemish agency for Innovation by Science and Technology (IWT) (Belgium) Infectious diseases Grant
2011-01-31 Amsterdam Molecular Therapeutics (The Netherlands) € 1.1 Million EU consortium Grant AIPGENE consortium The AIPGENE consortium is led by Fundación para la Investigatión Médica Aplicada (FIMA, Spain), and in addition to AMT, includes Clínica Universidad de Navarra (Spain), Stockholms Läns Landsting (Sweden), Deutsches Krebsforschungszentrum (Germany), Digna Biotech (Spain) and Servicio Madrileño de Salud (Spain). Rare diseases - Genetic diseases Grant
2011-01-27 Active Biotech (Sweden) SEK 375 million before transaction costs.(€ 42,595 million) private placement of 2,500,000 new shares Autoimmune diseases - Cancer - Oncology Private placement
2011-01-26 Microvisk Technologies (UK) £6 million (€ 7.02 million ) rights issue to existing investors Porton Capital, Oxford Technology Management, New Hill ( Boston , USA ), Midven, the Rainbow Seed Fund, Finance Wales and private investors. Cardiovascular diseases -Hematological diseases Fundraising
2011-01-21 InDex Pharmaceuticals (Sweden) SEK 75 million (€8.35 million) financing round Industrifonden (Sweden) - current investors - SEB Venture Capital Autoimmune diseases – Inflammatory diseases Fundraising
2011-01-20 Genfit (France) € 4.9 million ISI grant OSEO (France) Cardiovascular diseases - Metabolic diseases - Liver diseases Grant
2011-01-18 Diagnoplex (Switzerland) CHF 10 million (€7.7 million) series A financing round Debiopharm Group (Switzerland)
Novartis Venture Fund (Switzerland)
NeoMed (Switzerland)
Initiative Capital Romandie (Switzerland)
Cancer - Oncology Fundraising
2011-01-13 Complix (Belgium) €2 million series A financing round Credit Agricole Private Equity (France) Autoimmune diseases - Infectious diseases Fundraising
2011-01-12 Vaximm (Switzerland - Germany) CHF 7.8 million (€.14 million) financing round BB Biotech Ventures (UK) - Merck KGaA (Germany) - Sunstone Capital (Denmark) - Merck Serono Ventures (Germany - Switzerland) - BioMedPartners (Switzerland) Cancer - Oncology Fundraising
2011-01-12 Celyad previously known as Cardio3 Biosciences (Belgium) €3.1 million cash advance, grant Walloon Region (Belgium) - European Commission’s Seventh Framework Program (FP7) Cardiovascular diseases Grant
2011-01-12 Vaxxim (Germany) CHF 7.8 million financing round BB Biotech Ventures (Switzerland) Merck KGaA (Germany) Sunstone Capital (Denmark) Merck Serono Ventures (Switzerland) BioMedPartners (Switzerland) Cancer - Oncology Financing round
2011-01-10 Polyplus-transfection (France) € 2,5 million financing round AIRFI (Alsace Inter Regio Fonds d’Investissement) (France)Sudinnova (France)CIC Vizille Capital Innovation (France)CIC Finance (France) Technology - Services Fundraising
2011-01-06 Symphogen (Denmark) €141 million placement of preferred stock to a group of investors Novo A/S (Denmark Essex Woodlands (USA-UK) Danish Pension Fund PKA (Denmark) Cancer - Oncology Private placement
2010-06-29 Bind Biosciences (USA - MA) $23.4 million series C financing round DHK Investment (India) Polaris Venture Partners (USA - MA) Flagship Ventures (USA - MA) ARCH Venture Partners (USA - IL) Endeavour Vision (Switzerland) NanoDimension (USA - CA) new private investors Series C financing round
0000-00-00 Oasmia Pharmaceutical (Sweden) SEK 42 million (€ 4.4 million) private placement Cancer - Oncology - Veterinary medicine Private placement